Important Safety Information Prescribing Information This website is intended for US residents only.
Sancuso Logo

SANCUSO® (granisetron transdermal system) representative Health care provider site map

Indication and Important Safety Information

INDICATIONS AND USAGE

Sancuso® (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days.

CONTRAINDICATIONS

Sancuso is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the transdermal system.

WARNINGS AND PRECAUTIONS

Adverse Reactions

The most common adverse reaction (≥ 3%) is constipation.

You are encouraged to report suspected adverse reactions to Kyowa Kirin, Inc. at 1-800-Sancuso or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See full Prescribing Information for SANCUSO.